COVID-19
OraSure's Q1 Core Revenues Down 2 Percent
The firm brought in revenues of $29.9 million in Q1, down 45 percent from $54.1 million in Q1 2024 but narrowly beating the consensus Wall Street estimate of $29.6 million.
Diasorin Q1 Revenues Rise 8 Percent
The firm reported growth across its immunodiagnostics and molecular diagnostics businesses as well as contributions from the firm's licensed technologies business.
DOJ Reaches Total of $14M in Settlements in Two Separate Lab Fraud Cases
In one case, a firm is alleged to have improperly billed the COVID-19 Uninsured Program while in the other, a firm paid and received kickbacks for unnecessary genetic testing.
Diagnostics for the Real World Prepares to Launch Retooled Rapid Point-of-Care Testing Platform
Premium
The company, also known as DRW, shared early data on its forthcoming multiplex qPCR-based platform and infectious disease panels at the ESCMID global congress in Vienna.
On the heels of CLIA waiver, the Austin, Texas-based firm aims to submit additional respiratory tests for regulatory clearance.